Back to ranking
#1USNASDAQMid-cap

EXEL

Exelixis

$56.12USD

Data as of 2026-07-21

Fair value$28.37
Target$87.97
Loss chance46%Neutral

Company attributes

SizeLarge cap
SectorHealth Care
Dividend
TypeCommon stock

Price

Interactive 5-year price history chart for EXEL. Latest close $56.12.

Loading price history…

Pillar breakdown

0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)

Health Care median (n=166)
  • Quality
    Profit margins & asset efficiency
    95
    Exceptional
    Health Care median (n=166) 50
  • Value
    Price vs fundamentals
    59
    Strong
    Health Care median (n=166) 52
  • Growth
    Revenue & earnings trajectory
    88
    Exceptional
    Health Care median (n=166) 50
  • Momentum
    Recent price strength
    73
    Exceptional
    Health Care median (n=166) 49
  • Health
    Balance sheet & solvency
    80
    Exceptional
    Health Care median (n=166) 57
  • Profitability
    ROE, ROA, ROIC
    94
    Exceptional
    Health Care median (n=166) 48
  • Technical
    Trend & volatility signals
    54
    Average
    Health Care median (n=166) 56
  • Risk
    Volatility & drawdown profile
    64
    Strong
    Health Care median (n=166) 46
025405570100
Exceptional (70+)Strong (55–70)Average (40–55)Weak (25–40)Poor (<25)

Pillars not shown: Sentiment, ML (Phase 5+).

Fair price check

6 different valuation methods each estimate what EXELshould be worth, then we compare to today's price.

Looks overvalued
Models suggest EXEL is trading above fair value
Today's price
$56.12
Median fair price
$28.37
-49% vs today's price
Of 6 methods:2 say cheap4 say pricey
  • EV/EBITDAUndervalued
    thinks it's a bargainestimates $87.97, about 57% above today
  • P/E multiplesUndervalued
    thinks it's a bargainestimates $78.26, about 39% above today
  • P/B multiplesOvervalued
    thinks it's expensiveestimates $39.28, about 30% below today
  • DCF (2-stage)Overvalued
    thinks it's expensiveestimates $17.46, about 69% below today
  • Graham (defensive)Overvalued
    thinks it's expensiveestimates $17.03, about 70% below today
  • Residual IncomeOvervalued
    thinks it's expensiveestimates $12.66, about 77% below today

How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.

Fair price ensemble

Median fair
$28.37
Margin of safety(vs fair value)
-97.8%
Max (ex-outliers)
$87.97
Tangible BVPS
$7.45

Median of all applicable methods (current price $56.12). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.

Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.

Supporting dataRaw fundamentals & data-quality provenance behind the scores above

Raw fundamentals (SEC EDGAR)

MetricValue
Market cap$14.11B
Revenue (TTM)$2.38B
Net income (TTM)$833.42M
Operating cash flow (TTM)$924.67M
CapEx (TTM)$6.99M
Free cash flow (TTM)CFO − CapEx$917.69M
Total assets$2.59B
Total liabilities$657.85M
Stockholders' equity$1.94B
Cash & equivalents$226.15M
Shares outstanding251.36M
EPS (basic)$3.32
EPS (diluted)$3.32
P/E ratio (TTM)16.93

TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).

Data quality

Latest filed date
2026-05-05
Latest period end
2026-04-27
Filing lag
77 days
Missing metrics
6(gross_profit, interest_expense, income_before_tax, dividends_paid, accounts_receivable, intangibles_net)

Composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars are reserved for a later phase; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.